10x Genomics $TXG Stock Holdings Lessened by SVB Wealth LLC

Key Points

• SVB Wealth LLC reduced its stake in 10x Genomics by 17.9%, now holding 0.35% of the company, valued at approximately $3.75 million.
• Numerous institutional investors have modified their positions, with GAMMA Investing LLC increasing its holdings by 81.8% in the first quarter.
• Analysts have set a range of price targets for 10x Genomics, with current average ratings showing six "Buy," six "Hold," and one "Sell" rating.

SVB Wealth LLC lowered its stake in 10x Genomics (NASDAQ:TXG - Free Report) by 17.9% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 429,117 shares of the company's stock after selling 93,492 shares during the period. SVB Wealth LLC owned approximately 0.35% of 10x Genomics worth $3,746,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. GAMMA Investing LLC increased its holdings in shares of 10x Genomics by 81.8% in the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock valued at $31,000 after buying an additional 1,614 shares in the last quarter. Invesco Ltd. boosted its position in 10x Genomics by 21.8% during the 4th quarter. Invesco Ltd. now owns 118,067 shares of the company's stock worth $1,695,000 after acquiring an additional 21,134 shares during the period. Deutsche Bank AG boosted its position in 10x Genomics by 35.3% during the 4th quarter. Deutsche Bank AG now owns 10,190 shares of the company's stock worth $146,000 after acquiring an additional 2,657 shares during the period. Cetera Investment Advisers increased its holdings in shares of 10x Genomics by 22.7% in the 4th quarter. Cetera Investment Advisers now owns 19,898 shares of the company's stock valued at $286,000 after purchasing an additional 3,679 shares during the period. Finally, Rhumbline Advisers lifted its position in shares of 10x Genomics by 11.4% in the first quarter. Rhumbline Advisers now owns 120,490 shares of the company's stock worth $1,052,000 after purchasing an additional 12,374 shares in the last quarter. Institutional investors own 84.68% of the company's stock.

Analysts Set New Price Targets

TXG has been the topic of a number of research analyst reports. Morgan Stanley lowered their price objective on shares of 10x Genomics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 12th. Deutsche Bank Aktiengesellschaft set a $14.00 price objective on 10x Genomics and gave the company a "hold" rating in a research report on Friday, August 8th. Bank of America raised their price target on 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a research note on Thursday, June 26th. The Goldman Sachs Group lowered their price target on 10x Genomics from $7.50 to $6.50 and set a "sell" rating for the company in a research note on Monday, May 12th. Finally, Wall Street Zen raised shares of 10x Genomics from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Six analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $13.54.

10x Genomics Stock Up 9.2%

Shares of TXG stock opened at $14.30 on Friday. 10x Genomics has a 12 month low of $6.78 and a 12 month high of $24.76. The business's 50 day moving average is $12.59 and its two-hundred day moving average is $10.68. The company has a market cap of $1.78 billion, a PE ratio of -20.43 and a beta of 2.03.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of ($0.35) by $0.63. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The company had revenue of $172.91 million for the quarter, compared to the consensus estimate of $139.36 million. During the same quarter last year, the company posted ($0.32) earnings per share. The company's revenue for the quarter was up 12.9% compared to the same quarter last year. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, equities analysts expect that 10x Genomics will post -1.43 EPS for the current fiscal year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics (NASDAQ:TXG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.